CLOZAPINE DISPOSITION COVARIES WITH CYP1A2 ACTIVITY DETERMINED BY A CAFFEINE TEST

被引:259
作者
BERTILSSON, L
CARRILLO, JA
DAHL, ML
LLERENA, A
ALM, C
BONDESSON, U
LINDSTROM, L
DELARUBIA, IR
RAMOS, S
BENITEZ, J
机构
[1] KAROLINSKA INST,HUDDINGE HOSP,DEPT MED LAB SCI & TECHNOL,DIV CLIN PHARMACOL,S-14186 HUDDINGE,SWEDEN
[2] UNIV EXTREMADURA,SCH MED,DEPT PHARMACOL,E-06071 BADAJOZ,SPAIN
[3] UPPSALA UNIV,PSYCHIAT RES CTR,S-75017 UPPSALA,SWEDEN
关键词
CLOZAPINE; CAFFEINE; CYP1A2;
D O I
10.1111/j.1365-2125.1994.tb04385.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
In a previous study we showed that the disposition of clozapine after a single oral dose is unrelated to either debrisoquine or S-mephenytoin hydroxylation polymophism. The same 14 healthy subjects studied in that investigation were given 150 mg of caffeine. The reciprocal of plasma clozapine AUC (0,24), was correlated with an index of the N3-demethylation of caffeine (r(s) = 0.84; P = 0.0024), used as a measure of cytochrome P4501A2 (CYP1A2) activity. N1- and N7-demethylation indices of caffeine also reflect CYP1A2 activity and were also correlated with clozapine clearance (r(s) = 0.89 and 0.85; P = 0.0013 and 0.0023; respectively). No significant relationships with xanthine oxidase and N-acetyl transferase activity, also assessed by a caffeine test, were found. This study suggests that clozapine is metabolised by CYP1A2 to a major extent.
引用
收藏
页码:471 / 473
页数:3
相关论文
共 18 条
  • [1] BALDESSARINI RJ, 1991, NEW ENGL J MED, V324, P746
  • [2] THE DEBRISOQUINE HYDROXYLATION TEST PREDICTS STEADY-STATE PLASMA-LEVELS OF DESIPRAMINE
    BERTILSSON, L
    ABERGWISTEDT, A
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1983, 15 (03) : 388 - 390
  • [3] FLUVOXAMINE-TRICYCLIC ANTIDEPRESSANT INTERACTION - AN ACCIDENTAL FINDING
    BERTSCHY, G
    VANDEL, S
    VANDEL, B
    ALLERS, G
    VOLMAT, R
    [J]. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1991, 40 (01) : 119 - 120
  • [4] FLUVOXAMINE IS A POTENT INHIBITOR OF CYTOCHROME-P4501A2
    BROSEN, K
    SKJELBO, E
    RASMUSSEN, BB
    POULSEN, HE
    LOFT, S
    [J]. BIOCHEMICAL PHARMACOLOGY, 1993, 45 (06) : 1211 - 1214
  • [5] CAFFEINE METABOLISM IN A HEALTHY SPANISH POPULATION - N-ACETYLATOR PHENOTYPE AND OXIDATION PATHWAYS
    CARRILLO, JA
    BENITEZ, J
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 1994, 55 (03) : 293 - 304
  • [6] GENETICALLY VARIABLE METABOLISM OF ANTIDEPRESSANTS AND NEUROLEPTIC DRUGS IN MAN
    DAHL, ML
    BERTILSSON, L
    [J]. PHARMACOGENETICS, 1993, 3 (02): : 61 - 70
  • [7] DISPOSITION OF THE NEUROLEPTIC ZUCLOPENTHIXOL COSEGREGATES WITH THE POLYMORPHIC HYDROXYLATION OF DEBRISOQUINE IN HUMANS
    DAHL, ML
    EKQVIST, B
    WIDEN, J
    BERTILSSON, L
    [J]. ACTA PSYCHIATRICA SCANDINAVICA, 1991, 84 (01) : 99 - 100
  • [8] DISPOSITION OF CLOZAPINE IN MAN - LACK OF ASSOCIATION WITH DEBRISOQUINE AND S-MEPHENYTOIN HYDROXYLATION POLYMORPHISMS
    DAHL, ML
    LLERENA, A
    BONDESSON, U
    LINDSTROM, L
    BERTILSSON, L
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1994, 37 (01) : 71 - 74
  • [9] DAHLPUUSTINEN ML, 1989, CLIN PHARMACOL THER, V46, P781
  • [10] BIOTRANSFORMATION OF CAFFEINE, PARAXANTHINE, THEOBROMINE AND THEOPHYLLINE BY CDNA-EXPRESSED HUMAN CYP1A2 AND CYP2E1
    GU, L
    GONZALEZ, FJ
    KALOW, W
    TANG, BK
    [J]. PHARMACOGENETICS, 1992, 2 (02): : 73 - 77